|
|
 |
|
Viewing report
|
|
|
|
Netherlands Pharmaceuticals and Healthcare Report Q1 2010
Business Monitor International, Nov 2009, Pages: 77
The report calculates the Netherlands’ pharmaceutical expenditure to have been EUR5.8bn (US$8.5bn) in 2008. We expect drug expenditure to reach a value of EUR6.0bn in 2009. However, as a result of the weakening euro, drug expenditure in US dollar terms is expected to decline to US$8.45bn. By 2014, we expect the total amount spent on prescription and over-the-counter (OTC) medicines to have reached a value of EUR6.9bn (US$8.6bn), equating to a 2009-2014 CAGR of 2.7% in local currency terms and 0.27% in US dollar terms.
Our extended 10-year forecast model projects that drug expenditure will reach a value of EUR8.1bn (US$10.12bn) by 2019, representing a 2009-2019 CAGR of 3.04% in local currency terms and 1.81% in US dollar terms. As a proportion of GDP, drug expenditure is expected to decline marginally over the 10 years, from 1.04% in 2009 to 0.88% by 2019. The drop-off is anticipated due to stringent costcontainment measures by the government, including a greater use of generic medicines and drug price cuts.
In September 2009, the Dutch Ministry of Health said that for the first time, health insurers in the Netherlands will be allowed to include biosimilars in their preference policies. Insurers in the Netherlands can choose to reimburse only a certain selected generic medicine, unless a physician specifies on the prescription that the patient might have an adverse reaction to that particular product. In the same way, insurers can now select a biosimilar for reimbursement. BMI notes that the move is an attempt to cut spending on growth hormones by EUR10mn (US$15mn) by extending health insurer preference policies to include ‘the most cost-efficient variant of growth hormones’.
Global logistics firm UPS has opened a new facility in the Netherlands, dedicated to the storage and transport of medical devices and pharmaceutical products, therefore increasing its presence in the global healthcare logistics market. UPS’s facility in the Netherlands is designed to meet the growing customer demand for healthcare logistics in Europe and provide healthcare-compliant inventory management, temperature-sensitive storage and quality assurance services. While exports have been strong in the past, imports are expected to gain prominence in BMI’s forecast period, as the Netherlands continues to act as a notable regional distribution base. The Netherlands imports a significant amount of its medical devices and supplies. Additionally, around 80% of branded drugs are imported into the country, a significant proportion of which are then re-exported, mainly to countries within the EU.
In company news, a September 2009 deal valued at US$95mn in cash plus US$35mn on the achievement of milestones saw Netherlands-based molecular diagnostics company Qiagen acquire UK-based DxS, which designs, develops, manufactures and sells companion diagnostic products.
The Netherlands Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on the Netherlands' pharmaceuticals and healthcare industry.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Netherlands Pharmaceuticals and Healthcare Report Q1 2012
Netherlands Pharmaceuticals and Healthcare Report Q4 2011
Netherlands Pharmaceuticals and Healthcare Report Q4 2010
Netherlands Pharmaceuticals and Healthcare Report Q2 2012
Slovenia Pharmaceuticals and Healthcare Report Q1 2012
Hungary Pharmaceuticals and Healthcare Report Q1 2011
Morocco Pharmaceuticals and Healthcare Report Q1 2011
Estonia Pharmaceuticals and Healthcare Report Q2 2012
France Pharmaceuticals and Healthcare Report Q2 2012
Serbia Pharmaceuticals and Healthcare Report Q1 2011
|
|
|
|
